Crohn's disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti-inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) seems to play a central role in pathogenesis of CD. Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-α and its receptors. The aim of this paper is to critically review the rationale and state-of-the art for the TNF- α inhibitors in the treatment of CD. © 2007 Bentham Science Publishers Ltd.
Danese S., Pagano N., Angelucci E., Stefanelli T., Repici A., Omodei P., et al. (2007). Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: Tipping the balance. CURRENT MEDICINAL CHEMISTRY, 14(14), 1489-1497 [10.2174/092986707780831104].
Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: Tipping the balance
Pagano N.;
2007
Abstract
Crohn's disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti-inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) seems to play a central role in pathogenesis of CD. Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-α and its receptors. The aim of this paper is to critically review the rationale and state-of-the art for the TNF- α inhibitors in the treatment of CD. © 2007 Bentham Science Publishers Ltd.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


